Adicet Bio, Inc.
$8.67
▲
1.6%
2026-04-21 05:02:01
www.adicetbio.com
NCM: ACET
Explore Adicet Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$83.2 M
Current Price
$8.67
52W High / Low
$17.44 / $6.01
Stock P/E
—
Book Value
$14.82
Dividend Yield
—
ROCE
-71.49%
ROE
-67.55%
Face Value
—
EPS
$-16.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
102
Beta
1.58
Debt / Equity
9.26
Current Ratio
7.47
Quick Ratio
7.47
Forward P/E
-2.01
Price / Sales
—
Enterprise Value
$-71.13 M
EV / EBITDA
0.61
EV / Revenue
—
Rating
Strong Buy
Target Price
$53
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 2. | Rocket Pharmaceuticals, Inc. | $3.86 | — | $421.21 M | — | -76.11% | -60.27% | $8.26 / $2.19 | $2.56 |
| 3. | BioRestorative Therapies, Inc. | $0.26 | — | $6.72 M | — | -4386.1% | -3.2% | $2.04 / $0.19 | $0.04 |
| 4. | Stoke Therapeutics, Inc. | $36.46 | — | $2.16 B | — | -5.71% | -2.37% | $40.22 / $7.34 | $5.98 |
| 5. | Celldex Therapeutics, Inc. | $34.38 | — | $2.7 B | — | -54.02% | -40.62% | $35.29 / $17.45 | $7.92 |
| 6. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 7. | Nuvectis Pharma, Inc. | $8.33 | — | $235.78 M | — | -149.75% | -1.88% | $11.52 / $5.55 | $0.72 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -31.89 M | -27.95 M | -32.39 M | -29.89 M | -30.74 M | — |
| Net Profit | -30.52 M | -26.86 M | -31.22 M | -28.21 M | -28.73 M | — |
| EPS in Rs | -3.18 | -2.8 | -3.25 | -2.94 | -2.99 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 24.99 M |
| Operating Profit | -122.11 M | -127.61 M | -132.58 M | -72.55 M |
| Net Profit | -116.8 M | -117.12 M | -142.66 M | -69.79 M |
| EPS in Rs | -12.17 | -12.2 | -14.87 | -7.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 192.35 M | 220.22 M | 207.29 M | 330.69 M |
| Total Liabilities | 33.15 M | 33.61 M | 37.12 M | 38.35 M |
| Equity | 159.21 M | 186.61 M | 170.18 M | 292.34 M |
| Current Assets | 160.93 M | 180.14 M | 162.27 M | 261.04 M |
| Current Liabilities | 21.53 M | 19.39 M | 19.29 M | 19.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -95.25 M | -92.38 M | -93.72 M | -44.77 M |
| Investing CF | 2.39 M | -119.24 M | -4.46 M | -16.78 M |
| Financing CF | 75.25 M | 111.31 M | 0.24 M | 41.51 M |
| Free CF | -96.98 M | -93.5 M | -98.18 M | -61.55 M |
| Capex | -1.74 M | -1.12 M | -4.46 M | -16.78 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | -100% | — |
| Earnings Growth % | 0.27% | 17.9% | -104.41% | — |
| Profit Margin % | — | — | — | -279.27% |
| Operating Margin % | — | — | — | -290.32% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | -268.65% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-12-30 | 1:0.0625 |